Clonidine vs tizanidine for withdrawal syndrome

Comparison between clonidine and tizanidine as adjuvant therapy in managing opioid withdrawal syndrome in toxicology icu in Kosar hospital of Karaj and Loghman Hakim hostpital of Tehran

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210213050348N1

Enrollment

100

Registered

2021-05-01

Start date

2021-03-21

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid withdrawal syndrome. Opioid dependence with withdrawal

Interventions

Intervention group: Methadone and Tizanidine. Methadone from pharmaceutical company, 5mg q12h. Tizanidine from Aboureyhan pharmaceutical company, 4mg q12h , will be increased upto twice if signs are n

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All the hospitalized patients in toxicology ICU in hospitals Kosar of Karaj and Loghman Hakim of Tehran who are addicted to opioids

Exclusion criteria

Exclusion criteria: No consent from patient's family

Design outcomes

Primary

Measure	Time frame
The Objective Opiate Withdrawal Scale (OOWS). Timepoint: Evaluating OOWS score in 6, 12, 24, 72 and 120 hours after hospitalization. Method of measurement: By using OOWS questionnaire.	—

Secondary

Measure	Time frame
Sedation level. Timepoint: 6, 12, 24, 72 and 120 hours after hospitalization. Method of measurement: Recording level and content of consciousness.;Length of hospitalization. Timepoint: At the time of discharge. Method of measurement: Patient's charts.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoorvash Faraji Dana

Alborz University of Medical Sciences

f.drhoorvash@yahoo.com+98 26 3255 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026